(n)sometimes the FDA approves a drug for general use but requires the manufacturer to continue to monitor its effects; during this phase the drug may be tried on slightly different patient populations than those studied in earlier trials, Syn.phase IV
'%3e%3cpath%20d='M13.7001%2011.6957H3.30006C3.08006%2011.6957%202.90006%2011.8733%202.90006%2012.0904V12.8799C2.90006%2013.097%203.08006%2013.2746%203.30006%2013.2746H13.7001C13.9201%2013.2746%2014.1001%2013.097%2014.1001%2012.8799V12.0904C14.1001%2011.8733%2013.9201%2011.6957%2013.7001%2011.6957ZM15.3001%203.80096C14.6376%203.80096%2014.1001%204.33139%2014.1001%204.98517C14.1001%205.16034%2014.1401%205.32317%2014.2101%205.47366L12.4001%206.54438C12.0151%206.77136%2011.5176%206.64307%2011.2951%206.2582L9.25756%202.74011C9.52506%202.523%209.70006%202.19734%209.70006%201.82728C9.70006%201.17349%209.16256%200.643066%208.50006%200.643066C7.83756%200.643066%207.30006%201.17349%207.30006%201.82728C7.30006%202.19734%207.47506%202.523%207.74256%202.74011L5.70506%206.2582C5.48256%206.64307%204.98256%206.77136%204.60006%206.54438L2.79256%205.47366C2.86006%205.32563%202.90256%205.16034%202.90256%204.98517C2.90256%204.33139%202.36506%203.80096%201.70256%203.80096C1.04006%203.80096%200.500061%204.33139%200.500061%204.98517C0.500061%205.63895%201.03756%206.16938%201.70006%206.16938C1.76506%206.16938%201.83006%206.15951%201.89256%206.14965L3.70006%2010.9062H13.3001L15.1076%206.14965C15.1701%206.15951%2015.2351%206.16938%2015.3001%206.16938C15.9626%206.16938%2016.5001%205.63895%2016.5001%204.98517C16.5001%204.33139%2015.9626%203.80096%2015.3001%203.80096Z'%20fill='%23FFE713'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_3472_3618'%3e%3crect%20width='16'%20height='12.6316'%20fill='white'%20transform='translate(0.500061%200.643066)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)